Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 comparison of subcutaneous versus intravenous efgartigimod in healthy volunteers
NL-OMON49985Phase 1Completed
- Sponsor
- argenx
- Start
- Aug 2020
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in autoimmune disease, myasthenia gravis (MG), pemphigus and 1 more comparing Intravenous efgartigimod with Subcutaneous efgartigimod PH20 SC (2 arms). Primary endpoint: Noninferiority of pharmacodynamic effect on total IgG at Day 29. Started Aug 2020; status: completed.
02
Drugs
efgartigimod alfaENHANZE
03
Conditions
autoimmune diseasemyasthenia gravis (MG)pemphigusimmune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON49985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49985.